Planet 13 Announces Record Second Quarter 2019 Financial Results - Responsible for ~10% of Nevada's Cannabis Dispensary Sales
  • Q2 Revenue of $16.5 million, 19.5% sequential growth over Q1 2019
  • SuperStore accounted for 9.5% of all Nevada cannabis dispensary revenue in Q2 2019
  • Q2 EBITDA of $2.7 million, 105% sequential growth over Q1 2019
  • Well capitalized with $20 million in cash to complete all growth initiatives

All figures are reported in United States dollars ($) unless otherwise indicated

LAS VEGAS, Aug. 29, 2019 /CNW/ - Planet 13 Holdings Inc. (CSE: PLTH) (OTCQB: PLNHF) ("Planet 13" or the "Company"), a leading vertically-integrated Nevada cannabis company, today announced financial results for the three-month period ended June 30, 2019. Planet 13's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").

Cannabis Entertainment Complex (the "SuperStore") monthly performance since opening November 1st, 2018.












30-Nov-18

31-Dec-18

31-Jan-19

28-Feb-19

31-Mar-19

30-Apr-19

31-May-19

30-Jun-19

31-Jul-19

Revenue

$

3,364,891

$

3,438,723

$

4,075,052

$

4,304,122

$

5,456,889

$

5,276,095

$

5,884,363

$

5,361,193

$

5,428,543

MoM Growth


2.2%

18.5%

5.6%

26.8%

-3.3%

11.5%

-8.9%

1.3%

Total Tickets

42,157

44,296

48,119

48,052

61,602

58,869

64,930

60,323

60,044

# of Days

30

31

31

28

31

30

31

30

31

Average Customers/Day

1,405

1,429

1,552

1,716

1,987

1,962

2,095

2,011

1,937

Avg Ticket

$

79.82

$

77.63

$

84.69

$

89.57

$

88.58

$

89.62

$

90.63

$

88.87

$

90.41

Total Visitors

55,433

68,422

70,133

67,900

98,659

96,659

108,174

102,145

110,813

Avg Visitors/Day

1,848

2,207

2,262

2,425

3,183

3,222

3,489

3,405

3,575

Visitor Conversion Rate

76%

65%

69%

71%

62%

61%

60%

59%

54%











State of Nevada Sales

$

51,986,238

$

51,839,503

$

52,749,856

$

50,116,229

$

59,748,815

$

54,674,578

$

62,019,961

$

57,948,330

 Data not released yet 

% of State's Sales

6.5%

6.6%

7.7%

8.6%

9.1%

9.6%

9.5%

9.3%


 

Larry Scheffler, Co-CEO of Planet 13 commented, "Q2 was another great quarter for Planet 13 as SuperStore sales grew 19.4% sequentially over Q1.  Most of this revenue growth dropped to the bottom line with $2.7 million in EBITDA, a 105% sequential growth over Q1.  Planet 13's market share grew in Q2 accounting for 9.5% of all Nevada dispensary sales, compared to 7.9% in Q1.1  We are growing sales on both an absolute basis and as a percentage of the total market. Our Phase II expansion is progressing at full speed with the goal of opening at the end of Q3. Phase II which includes a 15,000 sq. ft. customer facing production facility, a restaurant, a coffee shop, and event space will build on Planet 13's leading position in Las Vegas by creating an experience no other dispensary can offer."

Bob Groesbeck, Co-CEO added, "We've had almost 800,000 visitors since we opened with approximately 80% coming from outside Nevada proving that if you want to build a national cannabis brand, you need to be in the SuperStore. As a part of Phase II, we will be launching new brands and significantly increasing the production of our existing successful brands for sale both in the SuperStore and wholesale across Nevada. Our 15,000 sq. ft. customer facing production facility will be unique in the industry as it has been designed to build a personal connection between our customers and our products. Nowhere else will customers be able to see the high-quality ingredients that go into their products, learn about the effects, and purchase all in one place."

Financial Highlights – Q2 – 2019

Operating Results

All comparisons below are to the quarter ended June 30, 2018, unless otherwise noted

  • Revenues were $16.5 million as compared to $4.4 million, an increase of 275%
  • Gross profit before biological adjustments was $9.7 million or 58.7% as compared $2.2 million or 50.8%, an increase of 333%
  • Operating expenses, excluding non-cash compensation expense, were $7.1 million as compared to $1.9 million, an increase of 280%
  • Net income before taxes of $1.1 million as compared to a net loss of $6.1 million
  • Net loss of $1.0 million as compared to a net loss of $6.9 million
  • Adjusted EBITDA of $2.7 million as compared to Adjusted EBITDA of $504,851

Balance Sheet

All comparisons below are to December 31, 2018, unless otherwise noted

  • Cash of $20.0 million as compared to $19.4 million
  • Total assets of $62.9 million as compared to $44.9 million, an increase of 40%
  • Total liabilities of $22.3 million as compared to $7.0 million, an increase of 216%

1 https://tax.nv.gov/Publications/Marijuana_Statistics_and_Reports/  [Note: Department of Taxation numbers are subject to revisions]

 

Q2 Highlights and Recent Developments

For a more comprehensive overview of these highlights and recent developments, please refer to Planet 13's Management's Discussion and Analysis of the Financial Condition and Results of Operations for the Three and Six Months Ended June 30, 2019 (the "MD&A").  

  • On May 24, 2019, Planet 13 announced upgrading to the OTCQX Best Market.
  • On May 29, 2019, Planet 13 announced national launch of Planet M CBD brand.
  • On June 6, 2019, Planet 13 announced California entry with marquee cannabis dispensary complex
  • On June 17, 2019, Planet 13 announced new flagship experience center with PAX
  • On July 29, 2019, Planet 13 announced new edible brands: HaHa Gummies™ and Dreamland Chocolates™

Marc Lustig Steps Down From Board of Directors

Effective August 28th, Marc Lustig has stepped down from the Planet 13 Board of Directors. In combination with the pending acquisition of CannaRoyalty Corp. dba Origin House by Cresco Labs Inc., Mr. Lustig will be focusing on his responsibilities as both a member of the senior management team of Cresco Labs, as well as its Board of Directors. 

Larry, Co-Chairman and Co-CEO commented, "We would like to express our gratitude to Marc, who has been an exemplary member of Planet 13's Board of Directors and was instrumental in the Company's pre-public and early public debut. I know I speak on behalf of the entire board in wishing Marc well in his new role at Cresco."

"It has been an honour to serve on the Planet 13 board and to contribute to the early growth of a Company that has plenty of runway to expand," said Marc Lustig. "Larry, Bob and the team have executed on the vision they articulated to the investment community and now have the highest grossing dispensary in the world, based on revenue. The SuperStore is rapidly becoming a must-visit destination in the entertainment capital of the world. It is with regret that I tender my resignation, but will continue to watch with anticipation as a significant shareholder, to see what is next for Planet 13."

Results of Operations (Summary)

The following tables set forth consolidated statements of financial information for the three-month and six-month period ending June 30, 2019 and June 30, 2018. For further information regarding the Company's financial results for these periods, please refer to the Company's interim financial statements for the period ended June 30, 2019 together with the MD&A, available on Planet 13's issuer profile on SEDAR at www.sedar.com and the Company's website https://www.planet13holdings.com.

Expressed in USD$

Three Months


Three Months




Six Months


Six Months




Ended


Ended


Percentage


Ended


Ended


Percentage


Jun-30-2019


Jun-30-2018


Change


Jun-30-2019


Jun-30-2018


Change

Revenue












Revenues, net of discounts

16,521,717


4,407,924


274.8%


30,357,780


7,995,466


279.7%

Cost of Goods Sold

(6,826,598)


(2,170,387)


214.5%


(13,220,044)


(4,118,561)


221.0%

Gross Profit, Before Biological Asset Adjustment

9,695,119


2,237,537


333.3%


17,137,736


3,876,905


342.0%

Gross Profit Margin %

58.7%


50.8%




56.5%


48.5%



Realized fair value amounts included in COGS

102,919


(1,893,227)


(105.4%)


(243,143)


(2,481,061)


(90.2%)

Unrealized fair value gain on growth of biological assets

(192,438)


1,956,264


(109.8%)


166,333


2,612,472


(93.6%)

Gross profit

9,605,600


2,300,574


317.5%


17,060,926


4,008,316


325.6%

Gross Profit Margin %

58.1%


52.2%




56.2%


50.1%















Expenses












General and Administrative

5,476,208


1,644,528


233.0%


10,016,428


2,755,501


263.5%

Sales and Marketing

1,644,752


229,363


617.1%


3,046,881


334,909


809.8%

Depreciation and Amortization

668,041


29,076


2197.6%


1,265,130


61,439


1959.2%

Share based payments

539,262


1,596,134


(66.2%)


1,111,614


1,596,134


(30.4%)

Total Expenses

8,328,263


3,499,101


138.0%


15,440,053


4,747,983


225.2%













Income (Loss) From Operations 

1,277,337


(1,198,527)


(206.6%)


1,620,873


(739,667)


(319.1%)













Other (Income) Expense:












Interest Expense, net

372,456


121,405


206.8%


588,155


239,857


145.2%

Realized Foreign Exchange gain (loss)

2,337


(10,721)


(121.8%)


5,062


(10,721)


(147.2%)

RTO acquisition costs

-


4,702,604


na


-


4,702,604


na

Other income

(161,678)


(18,245)


786.1%


(178,841)


(31,185)


473.5%

Loss on settlement of accounts payable (Note 13(d))

-


96,340


na


-


96,340


na

Total Other (Income) Expense

213,115


4,891,383


(95.6%)


414,376


4,996,895


(91.7%)













Income (loss) for the period before tax

1,064,222


(6,089,910)


(117.5%)


1,206,497


(5,736,562)


(121.0%)

Provision for tax - current

1,999,690


514,093


289.0%


3,565,309


854,728


317.1%

Income (Loss) for the period

(935,468)


(6,604,003)


(85.8%)


(2,358,812)


(6,591,290)


(64.2%)













Other Comprehensive (loss)












Items that may be reclassified subsequently to profit/loss 












Foreign exchange translation adjustment

(82,316)


(277,242)




190,889


(277,242)



Net Comprehensive Income  (Loss) for the period

(1,017,784)


(6,881,245)




(2,167,923)


(6,868,532)



Loss per share for the period












Basic and fully diluted loss per share

($0.01)


($0.08)




($0.02)


($0.08)















Weighted Average Number of Shares Outstanding












Basic and fully diluted

133,533,681


83,819,620




131,498,887


79,019,809















 

Adjusted EBITDA


Three Months


Three Months




Six Months


Six Months




Ended


Ended


Percentage


Ended


Ended


Percentage


Jun-30-2019


Jun-30-2018


Change


Jun-30-2019


Jun-30-2018


Change

EBITDA












Profit (loss) before taxes

1,064,222


(6,089,910)


(117.5%)


1,206,497


(5,736,562)


(121.0%)

Add back:












Net change in Inventory Bio Asset valuation

192,438


1,893,227


(89.8%)


(166,333)


2,481,061


(106.7%)

Net change in fair value inventory adjustments

(102,919)


(1,956,264)


(94.7%)


243,143


(2,612,472)


(109.3%)

Non-cash share based payments

539,262


1,596,134


(66.2%)


1,111,614


1,596,134


(30.4%)

Depreciation and amortization

668,041


29,076


2197.6%


1,265,130


61,439


1959.2%

Depreciation included in COGS

143,511


141,205


1.6%


286,987


258,788


10.9%

Interest and non-operating expesne (income)

213,115


4,891,383


(95.6%)


414,376


4,996,895


(91.7%)













EBITDA

2,717,670


504,851


438.3%


4,361,414


1,045,283


317.2%

Margin

16.4%


11.5%




14.4%


13.1%



 

 Summary of Quarterly Results

Three months ended

Jun-30-2019

Mar-31-2019

Dec-31-2018

Sep-30-2018

Jun-30-2018

Mar-31-2018

Dec-31-2017

Sep-30-2017

Jun-30-2017

US$










Total revenue

16,521,717

13,836,063

8,279,698

4,891,591

4,407,924

3,587,542

3,382,717

3,025,048

1,461,782

Net income (loss) 

(935,468)

(1,423,344)

(3,305,540)

(826,902)

(6,604,003)

12,741

259,493

(185,632)

22,209

Comprehensive Net Income (loss)

(1,017,784)

(1,150,138)

(3,972,510)

(685,610)

(6,881,245)

12,741

259,493

(185,632)

22,209

Net Income (loss) per share

(0.01)

(0.01)

(0.03)

(0.01)

(0.08)

 n/a 

 n/a 

 n/a 

 n/a 

Total assets

62,872,492

55,510,677

44,945,306

26,854,931

26,942,786

9,081,603

7,657,047

7,546,186

7,463,866

Total liabilities

22,279,348

17,656,059

7,040,566

4,857,506

5,957,754

8,314,441

10,839,575

11,680,362

11,760,007

Working capital

18,815,867

19,539,822

20,982,049

11,757,401

17,236,373

1,344,989

1,197,763

2,178,498

2,218,708

Dividends declared

-

-

-

-

-

-

-

-

-











 

Outstanding Shares

As at the date of this report, the Company had 81,220,432 common shares and 55,232,940 class A convertible, restricted voting shares issued and outstanding for a total of 136,453,372 shares outstanding.  There were 653,507 options issued and outstanding of which 176,842 have fully vested.  There were 16,103,615 warrants outstanding and 4,738,769 RSU's outstanding of which nil RSUs had fully vested as at the date of this report.

Conference Call

Planet 13 will host a conference call on Friday, August 30, 2019 at 8:30 a.m. EST to discuss its second quarter financial results and provide investors with key business highlights.  The call will be chaired by Bob Groesbeck, Co-CEO, Larry Scheffler, Co-CEO, and Dennis Logan, CFO. 

CONFERENCE CALL DETAILS

Date: August 30, 2019 | Time: 8:30 a.m. EST
Participant Dial-in: 416-764-8688 or 1-888-390-0546
Replay Dial-in: 416-764-8677 or 1-888-390-0541
(Available for 2 weeks)
Reference Number: 896749
Listen to webcast: https://bit.ly/2KslYdw

Financial Measures

There are measures included in this news release that do not have a standardized meaning under generally accepted accounting principles (GAAP) and therefore may not be comparable to similarly titled measures and metrics presented by other publicly traded companies. The Company includes these measures because it believes certain investors use these measures and metrics as a means of assessing financial performance. EBITDA (earnings before interest, taxes, depreciation and amortization) is calculated as net earnings before finance costs (net of finance income), income tax expense, and depreciation and amortization of intangibles and is a non-GAAP financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies.

About Planet 13
Planet 13 (www.planet13holdings.com) is a vertically integrated cannabis company based in Nevada, with award-winning cultivation, production and dispensary operations in Las Vegas - the entertainment capital of the world. Planet 13's mission is to build a recognizable global brand known for world-class dispensary operations and a creator of innovative cannabis products. Planet 13's shares trade on the Canadian Stock Exchange (CSE) under the symbol PLTH and OTCQX under the symbol PLNHF.

Cautionary Note Regarding Forward-Looking Information

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking statements relate to, among other things, future expansion plans.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: final regulatory and other approvals or consents; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Nevada cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in the State of Nevada; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational and medicinal cannabis marketplace in the United States through its subsidiary MMDC. Local state laws where MMDC operates permit such activities however, these activities are currently illegal under United States federal law. Additional information regarding this and other risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form dated April 30, 2019 filed on its issuer profile on SEDAR at www.sedar.com.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

Expressed in United States Dollars (unaudited)

As at


As at


June 30,


December 31,


2019


2018

Assets




Current Assets




Cash 

$

19,957,330


$

19,364,086

HST receivable

180,428


101,831

Inventories (Note 5)

5,846,474


5,322,111

Biological assets (Note 6)

374,245


915,177

Prepaid expenses and other current assets (Note 9)

4,171,830


1,391,278

Total Current Assets

30,530,307


27,094,483





Property and equipment (Note 7)

21,869,408


17,256,484

Right of use assets (Note 8)

9,808,438


-

Long-term deposits and other assets 

664,339


594,339


32,342,185


17,850,823

Total Assets

$

62,872,492


$

44,945,306





Liabilities




Current Liabilities




Accounts payable

$

3,231,142


$

1,720,721

Accrued expenses

1,562,390


1,306,145

Income taxes payable

6,036,908


2,187,109

Notes payable - current portion (Note 10)

884,000


884,000

Current portion of lease liabilities (Note 11)

-


14,459

Total Current Liabilities

11,714,440


6,112,434





Long -term lease liabilities (Note 11)

10,378,543


29,768

Deferred rent (Note 12)

-


427,508

Deferred tax liability (Note 15)

186,365


470,856


10,564,908


928,132

Total Liabilities

22,279,348


7,040,566





Shareholders' Equity




Share capital (Note 13)

48,566,345


42,460,824

Restricted share units (Note 13)

2,303,799


2,800,335

Warrants (Note 13)

6,172,980


7,046,843

Option reserve (Note 13)

427,094


305,890

Accumulated other comprehensive income (loss)

(612,030)


(802,920)

Deficit

(16,265,044)


(13,906,232)

Total Shareholders' Equity

40,593,144


37,904,740

Total Liabilities and Shareholders' Equity

$

62,872,492


$

44,945,306

 

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND
COMPREHENSIVE INCOME (LOSS)





As Restated




As Restated





(Note 3 (f) and 3(g))




(Note 3 (f) and 3(g))

Expressed in United States Dollars (unaudited)


Three months


Three months


Six months


Six months



Ended


Ended


Ended


Ended



June 30,


June 30,


June 30,


June 30,



2019


2018


2019


2018

Revenue









Revenues, net of discounts


$

16,521,717


$

4,407,924


$

30,357,780


$

7,995,466

Cost of Goods Sold (Note 5)


(6,826,598)


(2,170,387)


(13,220,044)


(4,118,561)

Gross Profit before fair value asset adjustment


9,695,119


2,237,537


17,137,736


3,876,905

Realized fair value amounts included in inventory sold


102,919


(1,893,227)


(243,143)


(2,481,061)

Unrealized fair value gain on growth of biological assets


(192,438)


1,956,264


166,333


2,612,472

Gross Profit


9,605,600


2,300,574


17,060,926


4,008,316










Expenses









General and Administrative (Note 14)


5,476,208


1,644,528


10,016,428


2,755,501

Sales and Marketing


1,644,752


229,363


3,046,881


334,909

Depreciation and Amortization


668,041


29,076


1,265,130


61,439

Share-Based Compensation Expense


539,262


1,596,134


1,111,614


1,596,134

Total Expenses


8,328,263


3,499,101


15,440,053


4,747,983










Income (Loss) From Operations 


1,277,337


(1,198,527)


1,620,873


(739,667)










Other Expense:









Interest expense, net


372,456


121,405


588,155


239,857

Realized foreign exchange (gain) loss


2,337


(10,721)


5,062


(10,721)

Other (income) expense


(161,678)


(18,245)


(178,841)


(31,185)

RTO listing expense (Note 3(g))




4,702,604


-


4,702,604

Loss on settlement of accounts payable (Note 13(d))




96,340


-


96,340

Total Other Expense


213,115


4,891,383


414,376


4,996,895










Income (Loss) before income taxes


1,064,222


(6,089,910)


1,206,497


(5,736,562)

Provision for tax - current (Note 15)


1,999,690


514,093


3,717,532


834,687

Provision for tax - deferred (Note 15)


-


-


(152,223)


20,041

Net income (loss) for the period


$

(935,468)


$

(6,604,003)


$

(2,358,812)


$

(6,591,290)










Other Comprehensive Income (Loss)


















Foreign exchange translation gain (loss)


(82,316)


(277,242)


190,889


(277,242)

Net Comprehensive Income (Loss) for the Period


$

(1,017,784)


$

(6,881,245)


$

(2,167,923)


$

(6,868,532)










Loss per share for the period









Basic and diluted loss per share (Note 16)


($0.01)


($0.08)


($0.02)


($0.08)










Weighted Average Number of Common Shares Outstanding









Basic and Diluted (Note 16)


133,533,681


83,819,620


131,498,887


79,019,809










 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS




As Restated




(Note 3 (f) and 3(g))

Expressed in United States Dollars (unaudited)

Six Months


Six Months


Ended


Ended


June 30,


June 30, 


2019


2018

Operating activities




Net income (loss) for the period

$

(2,358,812)


$

(6,591,290)

Add (deduct) non-cash items:




Share based payments (Note 13)

1,224,131


1,596,134

Depreciation and amortization (Note 7,8)

1,580,761


320,227

Loss on settlement of accounts payable

-


96,340

Share base payment to Carpincho shareholders on RTO

-


3,910,559

Settlement of AP for RSUs

-


346,206

Deferred tax liability (Note 15)

(284,491)


174,908

Realized fair value amounts included in inventory sold

(102,919)


2,481,061

Unrealized fair value gain on growth of biological assets

192,438


(2,612,472)

Non-cash interest expense

-


217,048





Net change in non-cash working capital




HST receivable

(78,597)


(47,060)

Inventories (Note 5)

(11,150)


(700,177)

Biological assets (Note 6)

(89,519)


285,340

Prepaid expenses and other assets (Note 9)

(2,780,552)


(641,272)

Long term deposits and other assets

(70,000)


-

Accounts payable 

1,510,420


148,936

Accrued expenses

256,246


412,246

Income tax payable

3,849,799


880,388

Cash flow provided by (used in) operating activities

2,837,755


277,122





Investing activities




Purchase of property, plant and equipment (Note 7)

(5,946,852)


(1,201,858)

Cash flow used in investing activities

(5,946,852)


(1,201,858)





Financing activities




Issuance of common shares and warrants (Note 13)

-


20,205,692

Issuance of shares on warrant and option exercises (Note 13)

3,744,711


-

Share and warrant issuance costs

-


(2,309,453)

Principal repayment on lease liabilities (Note 11)

(15,934)


(2,721)

Cash flow provided by (used in) financing activities

3,728,777


17,893,518





Net increase (decrease) in cash 

619,680


16,968,782

Cash  at beginning of the period

19,364,086


451,869

Net cash acquired on acquisition

-


34,678

Effect of foreign exchange on cash

(26,436)


(345,871)

Cash at end of the period

$

19,957,330


$

17,109,458





 

SOURCE Planet 13 Holdings Inc.

For further information: LodeRock Advisors Inc., Planet 13 Investor Relations, mark.kuindersma@loderockadvisors.com, (416) 519-2156 ext. 2230; Robert Groesbeck or Larry Scheffler, Co-Chief Executive Officers, ir@planet13lasvegas.com
:)